Bellerophon Therapeutics, Inc. 4
4 · Bellerophon Therapeutics, Inc. · Filed Dec 12, 2016
Insider Transaction Report
Form 4
Luehring Jens
Director10% Owner
Transactions
- Purchase
Common Stock
2016-12-09$0.56/sh+20,000$11,200→ 39,860 total
Holdings
- 3,549,804(indirect: See footnote)
Common Stock
Footnotes (1)
- [F1]These shares are owned directly by Linde North America, Inc. ("Linde"). Jens Luehring is a director and chief financial officer of Linde. Mr. Luehring disclaims beneficial ownership of all shares held by Linde, except to the extent of his pecuniary interest therein.